Humoral Immune Response to -Methylacyl-CoA Racemase and Prostate Cancer

Abstract

Assays to detect a humoral immune response against AMACR may have the potential to supplement PSA screening in identifying patients with clinically significant prostate cancer, especially those with intermediate PSA levels.